4//SEC Filing
Macias William L. 4
Accession 0001764013-24-000081
CIK 0001764013other
Filed
Apr 18, 8:00 PM ET
Accepted
Apr 19, 6:05 PM ET
Size
11.4 KB
Accession
0001764013-24-000081
Insider Transaction Report
Form 4
Immunovant, Inc.IMVT
Macias William L.
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-04-17$28.80/sh−6,136$176,717→ 379,794 total - Sale
Common Stock
2024-04-17$29.94/sh−1,796$53,772→ 377,998 total - Sale
Common Stock
2024-04-17$29.94/sh−79$2,365→ 377,650 total - Sale
Common Stock
2024-04-17$28.80/sh−269$7,747→ 377,729 total
Footnotes (4)
- [F1]On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 21,916 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 - $29.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.43 - $30.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F4]On June 11, 2021, the holder was granted 18,674 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on June 15, 2021, of which 1,167 of these RSUs vested on April 13, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Documents
Issuer
Immunovant, Inc.
CIK 0001764013
Entity typeother
Related Parties
1- filerCIK 0001864280
Filing Metadata
- Form type
- 4
- Filed
- Apr 18, 8:00 PM ET
- Accepted
- Apr 19, 6:05 PM ET
- Size
- 11.4 KB